Figure 2. Proportion of variation in antibody detection between 2017 and 2018 vs 2015 and 2016 at the French Reference Center for Paraneoplastic Neurological Syndromes.

Note the 112% increase in Ma2-associated paraneoplastic neurologic syndrome detection observed after immune checkpoint inhibitor introduction. No other onconeural antibody (Ab) targeting intracellular antigens demonstrated a similar increment. A lower increment is observed for the recently implemented neural surface Abs, ranging from 30% to 50%, probably reflecting their relatively novel adoption in clinical practice if compared with the former group.